List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
11 December 2015 | By Victoria White
NICE intends to recommend Lynparza (olaparib) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer after AstraZeneca provided more information on the drug...
23 November 2015 | By Victoria White
Perrigo will pay AstraZeneca $380 million upon completion of the transaction to acquire the rights to sell Entocort capsules...
13 November 2015 | By Victoria White
Tagrisso (AZD9291) is the only approved medicine indicated for patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer...
10 November 2015 | By Victoria White
Anifrolumab is a new monoclonal antibody against the type I interferon (IFN) receptor that inhibits the activity of all type I IFNs, which play a central role in lupus...
6 November 2015 | By Victoria White
The transaction will give AstraZeneca access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia...
29 October 2015 | By Victoria White
The trial is a milestone in cancer treatment as the first to show the benefits of ‘precision medicine’ in prostate cancer...
22 October 2015 | By Victoria White
Under the terms of the expanded agreement, AstraZeneca and Lilly will evaluate the safety and efficacy of a range of additional combinations across the companies’ portfolios...
20 October 2015 | By Victoria White
Commercial production will begin at the new state-of-the-art site early next year and will focus on final-stage manufacturing, packaging and quality control...
1 October 2015 | By Victoria White
Brodalumab is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signalling...
11 September 2015 | By Victoria White
The facility will eventually double AstraZeneca’s biologics manufacturing capacity in the US to meet the needs of the Company’s maturing pipeline...
9 September 2015 | By Victoria White
Data demonstrated that in 60 patients who received AZD9291 once daily in the first-line setting, 72% were progression free at 12 months...
9 September 2015 | By Victoria White
AstraZeneca and The University of Manchester are teaming up to harness clinical bioinformatics to deliver personalised healthcare for cancer patients...
4 September 2015 | By Victoria White
The FDA has approved Brilinta tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year...
2 September 2015 | By Victoria White
Positive results from RECAPTURE 1 and 2, Phase III studies evaluating the antibiotic Avycaz as a treatment for patients with cUTI, have been announced...
24 August 2015 | By Victoria White
AstraZeneca and Peregrine Pharmaceuticals are to evaluate the safety and efficacy of Peregrine’s bavituximab in combination with AstraZeneca’s durvalumab...
